2934 Stock Overview
J Frontier Co.,Ltd. engages in the healthcare sale, medical care sale, and healthcare marketing businesses in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
J Frontier Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,460.00 |
| 52 Week High | JP¥5,830.00 |
| 52 Week Low | JP¥2,303.00 |
| Beta | 0.68 |
| 1 Month Change | -23.72% |
| 3 Month Change | -37.08% |
| 1 Year Change | 3.36% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.90% |
Recent News & Updates
Shareholder Returns
| 2934 | JP Healthcare | JP Market | |
|---|---|---|---|
| 7D | -2.2% | 0.5% | 0.8% |
| 1Y | 3.4% | 2.1% | 26.5% |
Return vs Industry: 2934 exceeded the JP Healthcare industry which returned 2.1% over the past year.
Return vs Market: 2934 underperformed the JP Market which returned 26.5% over the past year.
Price Volatility
| 2934 volatility | |
|---|---|
| 2934 Average Weekly Movement | 7.8% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 2934's share price has been volatile over the past 3 months.
Volatility Over Time: 2934's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 255 | Atsuhiro Nakamura | jfrontier.jp |
J Frontier Co.,Ltd. engages in the healthcare sale, medical care sale, and healthcare marketing businesses in Japan. It is involved in various activities, including online medical care, medication guidance, as well as operates drug delivery platform, medical institutions, and operates dispensing pharmacy.
J Frontier Co.,Ltd. Fundamentals Summary
| 2934 fundamental statistics | |
|---|---|
| Market cap | JP¥12.14b |
| Earnings (TTM) | -JP¥1.71b |
| Revenue (TTM) | JP¥17.01b |
0.7x
P/S Ratio-7.1x
P/E RatioIs 2934 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2934 income statement (TTM) | |
|---|---|
| Revenue | JP¥17.01b |
| Cost of Revenue | JP¥9.08b |
| Gross Profit | JP¥7.93b |
| Other Expenses | JP¥9.64b |
| Earnings | -JP¥1.71b |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -346.37 |
| Gross Margin | 46.62% |
| Net Profit Margin | -10.05% |
| Debt/Equity Ratio | 105.3% |
How did 2934 perform over the long term?
See historical performance and comparison